Alpha blocker + placebo + solifenacin

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Urinary Bladder, Overactive

Conditions

Urinary Bladder, Overactive

Trial Timeline

Jun 1, 2008 โ†’ Mar 1, 2010

About Alpha blocker + placebo + solifenacin

Alpha blocker + placebo + solifenacin is a approved stage product being developed by Astellas Pharma for Urinary Bladder, Overactive. The current trial status is completed. This product is registered under clinical trial identifier NCT00699049. Target conditions include Urinary Bladder, Overactive.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00699049ApprovedCompleted

Competing Products

20 competing products in Urinary Bladder, Overactive

See all competitors
ProductCompanyStageHype Score
Duloxetine + placeboEli LillyPhase 2
52
DuloxetineEli LillyPhase 2
52
Enfortumab vedotinAstellas PharmaPhase 1
33
solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
85
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
52
SolifenacinAstellas PharmaApproved
85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
77
Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
85
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaPre-clinical
23
TamuslosinAstellas PharmaPhase 3
77
Tamsulosin + SolifenacinAstellas PharmaApproved
85
mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placeboAstellas PharmaPhase 3
77
solifenacin succinate + tolterodineAstellas PharmaPhase 3
77
TamusulosinAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
77
Solifenacin succinate + PlaceboAstellas PharmaPhase 3
77
VesicareAstellas PharmaPre-clinical
23